On April 7, 2020 John Furey was appointed by the Board of Directors of Adaptimmune Therapeutics plc to replace Giles Kerr as a member of the Company's Audit Committee effective May 29, 2020. The Board has determined that Mr. Furey, who has served on the Board and as a member of the Company's Remuneration Committee since July 2018, meets the independence requirements of Rule 10A-3 under the Securities Exchange Act of 1934, as amended, and the applicable Nasdaq rules. Mr. Kerr, who has served on the Board since November 2016, will retire from office and has confirmed that he will not stand for re-election as a director at the Company's Annual General Meeting to be held on May 29, 2020 (the 2020 AGM) due to other time commitments. Mr. Kerr's decision not to pursue re-election was not due to a disagreement with the Company. Mr. Kerr will continue to serve as a director of the Company and as a member of the Company's Audit Committee and its Corporate Governance and Nominating Committee until the end of the 2020 AGM.